Introduction
With the advent of transcatheter aortic valve replacement (TAVR) for severe symptomatic aortic stenosis (AS), echocardiographic parameters that inform prognosis have been emphasized. 1 In general, these analyses have focused on the left ventricle, though more recently, progression to right ventricular (RV) damage has also shown prognostic importance. 2 After cardiac surgery, the association between baseline RV dysfunction and poor outcomes is established. 3 However, in the PARTNER II inoperable cohort, baseline RV dysfunction was associated with worse outcomes after TAVR on univariable, but not multivariable, analyses. 4 In addition, deterioration in RV function has been noted after surgical aortic valve replacement (SAVR), 5 but whether RV function worsens after TAVR remains unclear. 6 Specifically, in patients randomized to TAVR or SAVR, the differential incidence of worsening RV function and possible associations with adverse outcomes have not been well studied. Given this limited understanding of the importance of the RV after aortic valve replacement (AVR), the objectives of the current study are two-fold. First, in patients from PARTNER IIA, 7 we aim to delineate whether the approach to AVR has a differential impact on RV function. Second, we aim to determine whether worsening RV function after AVR is associated with adverse outcomes.
Methods

Study population
The PARTNER IIA study design and results have been previously reported. 7 In brief, 2032 patients with severe symptomatic AS were randomized to SAVR or TAVR with the Edwards Sapien XT valve. All patients were at intermediate risk, based on a Society of Thoracic Surgery (STS) predicted 30-day mortality of at least 4.0%. For this analysis, the logistic EuroSCORE was used instead of the STS score because the former includes the presence of pulmonary hypertension in calculating risk, an important parameter for right heart function. Our substudy included all patients with a core lab echocardiogram at baseline and at 30 days (n = 1384). We excluded patients with severe baseline RV dysfunction (n = 8), as we were specifically interested in patients with worsening RV function after AVR, yielding a final cohort of 1376 patients. The study protocol was approved by the institutional review board at each enrolling site, was compliant with the Declaration of Helsinki, and all patients provided written informed consent.
Echocardiography
An independent core laboratory prospectively analysed all echocardiograms with quality and measurement methodology as previously reported. 8, 9 In brief, the severity of AS was determined by measuring peak and mean gradients across the valve with the modified Bernoulli equation, and aortic valve area was calculated using the continuity equation. Ventricular size, left ventricular ejection fraction (LVEF), and left ventricular (LV) mass were measured according to the recommendations of the American Society of Echocardiography. 10 The severity of aortic, mitral, and tricuspid regurgitation (TR) were determined by an integrated, semiquantitative approach, as recommended by the American Society of Echocardiography. 11 RV size and function was also assessed with a guideline-endorsed multiparametric approach using visual assessment, right ventricular fractional area change when feasible, and tricuspid annular plane systolic excursion when available. 12 RV function was categorized as normal, mildly, moderately or severely decreased. In patients with RV dysfunction, severity was primarily based on visual assessment. Similarly, in accordance with guidelines, 12 RV enlargement was assessed visually, and dilation was defined from a dedicated apical view with linear dimensions if basal diameter was >42 mm, >35 mm at the mid level, or >86 mm in longitudinal dimension. 12 
Outcomes
Worsening RV function was defined as deterioration by at least one grade between baseline and 30-day echocardiogram. To assess outcomes, we performed a landmark analysis with all events occurring at least 30 days after AVR. As our primary outcome, we assessed whether worsening RV function was associated with all-cause mortality between 30 days and 2 years. For our secondary outcome, we assessed whether worsening RV function was associated with cardiovascular mortality between 30 days and 2 years. Other secondary outcomes included cardiac rehospitalizations that were not related to study valve or procedurdal complications, Kansas City Cardiomyopathy Questionnaire (KCCQ) 13 scores, and 6 min walk distance (m), all assessed between 30 days and 2 years. To assess whether complications may be related to worsening RV function, we also evaluated cardiac rehospitalizations that were related to the study valve or procedure.
Statistics
Continuous data were summarized as mean (standard deviation) or median (interquartile percentages) with comparisons using t-tests or Wilcoxon rank sum tests, and categorical data were expressed as n (%) with comparisons using the v 2 or Fisher exact tests, as appropriate.
Multivariable logistic regression was performed to assess associations with worsening RV function. Time-to-event curves for 30 day to 2 year mortality were created using the Kaplan-Meier estimates with between group comparisons using the log-rank test. For time-to-event outcomes, univariable and multivariable Cox proportional hazards models were created, and the assumptions of proportional hazards were satisfied. All covariates for the multivariable models were chosen based on biologic plausibility. A two-sided P-value of <0.05 was considered statistically significant. All statistical analyses were performed with SAS software, version 9.4 (SAS Institute) or R Core Team (2017).
Results
Baseline clinical and echocardiographic findings
From an initial 2032 patients, 1376 patients with paired baseline and 30 day echocardiograms were included in this study. Within the first 30 days, 34 patients with TAVR and 38 patients with SAVR died. As would be expected, patients alive and with echocardiograms at 30 days were slightly lower risk compared to PARTNER IIA patients not included in this substudy (see Supplementary material online, Table S1 ). Importantly, there were no statistically significant between group differences in TAVR and SAVR patients in this landmark analysis, except that SAVR patients were more likely to have atrial fibrillation at baseline (29.7% vs. 35 .6%, P = 0.02)(see Supplementary material online, Figure 1 . At baseline, patients with worsening RV function were more likely to have atrial fibrillation, and there was a trend towards higher logistic EuroSCOREs, male sex, permanent pacemaker, and New York Heart Association (NYHA) Class III or IV symptoms ( Table 1) .
Regarding echocardiographic parameters, worsening RV function was associated with lower LV systolic function, though most patients had normal LVEFs ( Table 1) . In addition, patients with worsening RV function were more likely to have dilated right ventricles at baseline, but there was no statistically detectable difference in baseline RV systolic function. Moderate or severe TR was also more common in patients who developed worsening RV function, and baseline estimated right ventricular systolic pressure (RVSP) was also higher, though absolute between group differences in RVSP were small ( Table 1) .
Worsening right ventricular function
In a multivariable model, SAVR was associated with a higher odds of worsening RV function compared with TAVR (OR 4.05, 95% CI 2.55-6.44). After adjustment, baseline clinical variables were not associated with worsening RV function, though the association with certain baseline echocardiographic variables remained significant. Specifically, patients with more than mild TR, lower LVEFs and dilated right ventricles at baseline were more likely to develop worsening RV function ( Table 2) . In stability analyses using the same covaraites but restricted to patients with either TAVR or SAVR, differential associations with worsening RV function were noted. For patients with TAVR, more than mild TR was associated with worsening RV function (OR 5.33, 95% CI 1.46-19.39 ), whereas an association with baseline RV dilation was not statistically detectable (OR 1.92, 95% CI 0.76-4.85) (see Supplementary material online, Table S3 ). Conversely, in patients with SAVR, baseline RV dilation was associated with worsening RV function (OR 2.77, 95% CI 1.35-5.68), and there was not a significant association with more than mild TR (OR 1.78, 95% CI 0.71-4.49) (see Supplementary material online, Table S4 ).
Regarding complications leading to cardiac rehospitalization, 30 events were study-valve related and 31 events were procedure related. Worsening RV function was not associated with either studyvalve related [hazard ratio (HR) 1.13 , 95% CI 0.43-2.95] or procedure related rehospitalization (HR 1.56, 95% CI 0.67-3.61). To assess exposures that were specific to either TAVR or SAVR and potential associations with worsening RV function, further exploratory analyses were performed. In SAVR, cardiopulmonary bypass time was not increased in patients with worsening RV function (108 vs. 100 min, P = 0.16) (see Table S5 ). For TAVR, post-dilation was not associated with worsening RV function (24.6% vs. 20 .6%, P = 0.46) (see Supplementary material online, Table S5 ). The need for a pacemaker after AVR was also not associated with worsening RV function after TAVR (16.1% vs. 11 .6%, P = 0.22) or (SAVR 10.9% vs. 11 .1%, P = 0.47) (see Supplementary material online, Table S5 ).
Supplementary material online,
Worsening right ventricular function and adverse events
Between 30 days and 2 years, there were 169 deaths, and patients with worsening RV function had higher mortality (HR 1.98, 95% CI 1.40-2.79) (Take home figure) . In comparing TAVR to SAVR, there was no difference in patients with (HR 1.16 , 95% CI 0.61-2.18) or without RV worsening (HR 1.03, 95% CI 0.72-1.48) (P-value for interaction 0.76). Regarding cardiovascular death, there were 85 events. Results were similar with higher cardiovascular death among patients with worsening RV function (HR 2.11, 95% CI 1.22-3.66) (Figure 2) . Regarding cardiac rehospitalizations that were not related to valve or procedural complications, there were 133 events, and there was not a statistically significant association with worsening RV function (HR 1.43, 95% CI 0.94-2.18).
To further assess the association between worsening RV function after AVR and adverse events, baseline echocardiographic variable were added separately to a background model that included age, sex, logistic EuroSCORE, and LVEF. After additional adjustment for baseline RV function, mitral regurgitation, and TR, the association between worsening RV function and all-cause death remained significant in all models with an approximately two-fold increase in hazard ( Table 3) . Results were similar for cardiovascular death, though the association was attenuated following adjustment for RVSP (HR 1.82, 95% CI 0.95-3.48) ( Table 4) . A graded response to magnitude of worsening RV function was also noted. Patients who began with normal RV function and developed moderate to severe dysfunction (n = 29) had the highest hazard for all-cause death (HR 2.87, 95% CI 1.40-5.89), followed by patients who initially had normal RV function and then developed mild dysfunction (n = 108)(HR 2.05, 95% CI 1.38-3.04) (Figure 3) . Similar results were obtained for cardiovascular death with the worst prognosis among patients with normal RV function who developed moderate to severe RV dysfunction (HR 4.37, 95% CI 1.87-10.2), followed by patients who worsened to mild RV dysfunction (HR 1.93, 95% CI 1.08-3.43) (Figure 4) . In patients with mild RV dysfunction at baseline who improved to normal RV function at 30 days (n = 49), there was no significant association with all-cause (HR 0.76, 95% CI 0.28-2.05) or cardiac death (HR 0.85, 95% CI 0.18-3.10).
In the entire cohort, patients with worsening RV function had a smaller increase in KCCQ scores from baseline to 30 days (6.1 vs. 11.1, P = 0.01). However, this association was related to smaller increases in KCCQ scores among patents with SAVR compared with TAVR (see Supplementary material online, Table S6 ). In addition, among SAVR patients with worsening RV function, there was less improvement in KCCQ scores compared with baseline at one (17.1 vs. 22 .8, P = 0.02) and 2 years (15.9 vs. 20.4 , P = 0.10), though none of these associations were significant after adjusting for multiple comparisons (see Supplementary material online, Table S6 ). Similarly, there were no significant differences in change in 6 min walk distance for patients with worsening RV function, stratified by TAVR or SAVR (see Supplementary material online, Table S7 ). With regards to the need for diuretics, in TAVR patients, there was no statistically detectable difference in those with and without worsening RV function at baseline, 30 days, 1 and 2 years (see Supplementary material online, Table S8) . Conversely, in patients with SAVR, even though there were no statistically significant differences after adjusting for multiple comparisons, a trend was noted: patients with worsening RV function were numerically more likely to require diuretic therapy at one (OR 1.61, 95% CI 1.07-2.43) and 2 years (OR 1.40, 95% CI 0.91-2.16) (see Supplementary material online, Table S8 ).
At 1-year, among patients with worsening RV function, 26 patients died, and 50 patients improved to normal RV function. When compared with TAVR, patients with SAVR were not more likely to improve to normal RV function at 1-year (OR 1.59, 95% CI 0.75-3.37). By two years of follow-up, 44 patients with worsening RV function had died, and 49 patients had normal RV function. Patients with SAVR were again not more likely to have normal RV function (OR 1.10, 95% CI 0.48-2.55).
Discussion
To the best of our knowledge, our study is the first to investigate adjusted analyses of worsening RV function after AVR and its association with adverse outcomes in patients randomized to SAVR or Right ventricular function after AVR TAVR. Several observations are notable. First, after multivariable adjustment, the odds for worsening RV function was more than four times greater for SAVR compared to TAVR. Worsening RV function was also more common in patients with dilated RVs and at least moderate TR. After adjusting for baseline clinical and echocardiographic parameters, worsening RV function was associated with higher allcause and cardiovascular mortality. Finally, a graded 'dose' response was noted. Patients who developed moderate or severe RV dysfunction from baseline normal RV function had the worst prognosis.
Previous studies of aortic valve replacement and right ventricular function
Right ventricular dysfunction after cardiac surgery is well-described, associated with adverse outcomes, and is generally attributed to ischaemia and myocardial depression following cardiopulmonary bypass without salutary unloading, as is often observed with the left ventricle when treating left-sided valvular lesions. [14] [15] [16] With the advent of TAVR, the prognostic importance of the right ventricle has been further emphasized. Results have been discordant with several investigations demonstrating that right ventricular dilation and dysfunction are associated with increased mortality whereas other studies have not confirmed this association. 4, [17] [18] [19] These discrepant results are possibly related to differences in cohorts, variations in methodologies for RV assessment, and the approach to multivariable adjustment. Importantly, these studies assessed baseline RV function and adverse events without investigating whether deterioration in RV function after AVR is associated with poor outcomes. More recently, however, a single-centre study investigated RV dysfunction after TAVR in over 1000 patients. 20 Their results are concordant with ours as Asami et al. 20 demonstrated a gradient of increasing risk from patients with normal RV function, to patients with new RV dysfunction, to patients with persistent RV dysfunction after TAVR. Of note, this study did not include patients with SAVR. Therefore, the differential incidence and impact of worsening RV function according to mode of AVR could not be investigated. Additional studies have demonstrated that RV dysfunction is more common after SAVR compared to TAVR. 5, 6, 21 However, these studies have either not involved randomized patients 5, 6 or did not perform adjusted analysis for worsening RV function after AVR. 22 Furthermore, like previous investigations involving patients with TAVR, 4, [17] [18] [19] 21 none of the prior studies addressed the possible association of worsening RV function after AVR and increased mortality. 5, 6, 21 Limitations Notable limitations of this study warrant emphasis. First, this study is a landmark analysis of patients from PARTNERIIA who had echocardiograms at 30 days, and these patients were slightly lower risk compared with patients who did not have 30 day echocardiograms (see Supplementary material online, Table S1 ; median logistic EuroSCORE in analysis of 6.3 vs. 7 .3 not in analysis). Of note, however, baseline Right ventricular function after AVR characteristics of TAVR and SAVR patients in this analysis were wellbalanced (see Supplementary material online, Table S2 ). Second, even though an integrated prospective echocardiographic approach was employed to evaluate RV function, guidelines to assess RV function have been updated since the initiation of PARTNERIIA 23 , and an even more accurate and reproducible assessment may be possible with global longitudinal strain and cardiac magnetic resonance imaging. [24] [25] [26] In particular, our approach emphasized visual assessment to categorize RV dysfunction. However, this approach reflects clinical practice, and we speculate that a more precise assessment of RV function would only strengthen the associations that we have demonstrated. Third, even though LVEF was associated with worsening RV function, absolute between group differences were small, and the majority of patients had normal or mildly reduced LVEFs. Therefore, our results are not as generalizable to patients with more severely reduced LV systolic function. Fourth, invasive haemodynamic data were not available. Baseline cardiac indices and intracardiac pressures may have provided further insights regarding associations with worsening RV function and adverse outcomes. Finally, our longitudinal analyses regarding changes in RV function and quality of life assessments at one and two years should be considered as merely descriptive and exploratory for two analytical reasons. First, after correction for multiple hypothesis testing, none of the results are statistically significant. Second, there are competing risks and events are likely not independent, as patients who die during follow-up would also be expected to have a worse performance on quality of life measures.
Clinical implications and future directions
Among an intermediate-risk cohort with severe symptomatic AS, patients with dilated RVs, more than mild TR, and patients treated with SAVR are at-risk for developing worsening RV function after AVR. After AVR, the extent to which specific insults contribute to worsening RV function are not well understood. Possible risks specific to SAVR include cardioplegia and pericardiotomy, whereas LV and RV interaction as well as alterations in the geometry of the fibrous skeleton may contribute to worsening RV function after TAVR or SAVR. [27] [28] [29] Even though these mechanisms are still being defined, and despite overall similar outcomes in patients with SAVR or TAVR once RV function has worsened, our results demonstrate that patients with worsening RV function after AVR have increased mortality. Exploratory analyses also suggested differential increased risks for worsening RV function in patients with TAVR or SAVR. With TAVR, more than mild TR, but not RV dilation, was associated with worsening RV function. Conversely, after SAVR, RV dilation, but not baseline TR, was associated with worsening RV function. Combined with other investigations and future studies, these results have implications regarding which intermediate risk patients may benefit from TAVR or SAVR. In addition, these results prompt the question of whether medical, surgical, and percutaneous treatment of concomitant TR can preserve RV function. Finally, our results should lead to further investigations of RV function after AVR in lower risk patients being considered for SAVR or TAVR. Most importantly, clinicians should recognize that patients with normal baseline RV function who develop moderate or severe dysfunction after AVR are at especially high risk.
